Sinovant Sciences Announces Approval of Derazantinib’s Clinical Trial Application by the China National Medical Products Administration

30. April 2019 INDIZES USA

ArQule, Inc.’s (Nasdaq: ARQL) partner, Sinovant Sciences, announced that its Clinical Trial Application (CTA) for derazantinib …
(Orginal – Story lesen…)

Tags: dow jones nasdaq s&p 500

You may also like...